Karolinska, Pasteur and UCSD researchers have developed a cellular fluorescence assay that can efficiently screen for potent transcription factor allosteric modulators during lead identification. Unlike compounds that work by binding targets’ active sites, allosteric modulators...

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...

INDICATION: Brain cancer Cell culture and mouse studies suggest nanoparticles loaded with siRNAs targeting SOX2 , OLIG2 , SALL2 , and POU3F2 could help treat the proneural subtype of glioblastoma multiforme (GBM). In two proneural GBM cell lines,...

University of Cambridge spinout Elpis Biomed Ltd. has a platform that rapidly produces stockpiles of pure, mature cell types from human pluripotent stem cells. While the company is first focusing on creating well-defined disease models,...

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...

TECHNOLOGY: Cell models A method for differentiating hPSCs into specific cell types by expressing select transcription factors could aid the development of cell-based disease models. The method involved engineering hPSCs via CRISPR-associated protein 9 (Cas9)-guided...

In September, newco Curtana received exclusive, worldwide rights to preclinical small molecule inhibitors against oligodendrocyte transcription factor 2 (OLIG2) from the university to treat glioblastoma multiforme and other cancers. Curtana plans to submit an IND...

Separate groups at the Case Western Reserve University School of Medicine and the Stanford University School of Medicine have developed similar approaches to directly reprogram rodent fibroblasts into oligodendrocyte progenitor cells. 1,2 The direct lineage...

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Fibroblast-derived induced oligodendrocyte progenitor cells (iOPCs) to treat myelination disorders Two separate studies developed methods to reprogram mouse fibroblasts into iOPCs...